205 related articles for article (PubMed ID: 36369379)
1. Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy.
Gu Y; Zhang P; Wang J; Lin C; Liu H; Li H; He H; Li R; Zhang H; Zhang W
Cancer Immunol Immunother; 2023 May; 72(5):1199-1208. PubMed ID: 36369379
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome and molecular landscape of patients with ARID1A-loss gastric cancer.
Sun M; Gu Y; Fang H; Shao F; Lin C; Zhang H; Li H; He H; Li R; Wang J; Liu H; Xu J
Cancer Sci; 2024 Mar; 115(3):905-915. PubMed ID: 38148578
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and immune infiltration significance of ARID1A in TCGA molecular subtypes of gastric adenocarcinoma.
Zhang Z; Li Q; Sun S; Ye J; Li Z; Cui Z; Liu Q; Zhang Y; Xiong S; Zhang S
Cancer Med; 2023 Aug; 12(16):16716-16733. PubMed ID: 37366273
[TBL] [Abstract][Full Text] [Related]
4. The impact of ARID1A mutation on molecular characteristics in colorectal cancer.
Tokunaga R; Xiu J; Goldberg RM; Philip PA; Seeber A; Battaglin F; Arai H; Lo JH; Naseem M; Puccini A; Berger MD; Soni S; Zhang W; Chen S; Hwang JJ; Shields AF; Marshall JL; Baba H; Korn WM; Lenz HJ
Eur J Cancer; 2020 Nov; 140():119-129. PubMed ID: 33080474
[TBL] [Abstract][Full Text] [Related]
5. Dramatic Response to Pembrolizumab Monotherapy in a Patient With ARID1A-Mutant Lung Adenocarcinoma: Case Report.
Harada G; Amano MT; Antonacio FF; Behar MH; Nabuco-de-Araujo PHX; Buchpiguel CA; Junior GC
Clin Lung Cancer; 2021 Sep; 22(5):e708-e711. PubMed ID: 33658161
[TBL] [Abstract][Full Text] [Related]
6. ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability.
Abe H; Maeda D; Hino R; Otake Y; Isogai M; Ushiku AS; Matsusaka K; Kunita A; Ushiku T; Uozaki H; Tateishi Y; Hishima T; Iwasaki Y; Ishikawa S; Fukayama M
Virchows Arch; 2012 Oct; 461(4):367-77. PubMed ID: 22915242
[TBL] [Abstract][Full Text] [Related]
7. Loss of ARID1A Expression is Related to Gastric Cancer Progression, Epstein-Barr Virus Infection, and Mismatch Repair Deficiency.
Han N; Kim MA; Lee HS; Kim WH
Appl Immunohistochem Mol Morphol; 2016; 24(5):320-5. PubMed ID: 26067140
[TBL] [Abstract][Full Text] [Related]
8. Impact of intratumoural CD96 expression on clinical outcome and therapeutic benefit in gastric cancer.
Xu C; Fang H; Gu Y; Yu K; Wang J; Lin C; Zhang H; Li H; He H; Liu H; Li R
Cancer Sci; 2022 Dec; 113(12):4070-4081. PubMed ID: 35997524
[TBL] [Abstract][Full Text] [Related]
9. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer.
Mehrvarz Sarshekeh A; Alshenaifi J; Roszik J; Manyam GC; Advani SM; Katkhuda R; Verma A; Lam M; Willis J; Shen JP; Morris J; Davis JS; Loree JM; Lee HM; Ajani JA; Maru DM; Overman MJ; Kopetz S
Clin Cancer Res; 2021 Mar; 27(6):1663-1670. PubMed ID: 33414133
[TBL] [Abstract][Full Text] [Related]
10. ARID1A deficiency in EBV-positive gastric cancer is partially regulated by EBV-encoded miRNAs, but not by DNA promotor hypermethylation.
Kase K; Saito M; Nakajima S; Takayanagi D; Saito K; Yamada L; Ashizawa M; Nakano H; Hanayama H; Onozawa H; Okayama H; Endo H; Fujita S; Sakamoto W; Saze Z; Momma T; Mimura K; Ohki S; Shiraishi K; Kohno T; Kono K
Carcinogenesis; 2021 Feb; 42(1):21-30. PubMed ID: 33196828
[TBL] [Abstract][Full Text] [Related]
11. ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report.
Durán M; Faull I; Lastra E; Laes JF; Rodrigo AB; Sánchez-Escribano R
J Med Case Rep; 2021 Feb; 15(1):89. PubMed ID: 33608032
[TBL] [Abstract][Full Text] [Related]
12. ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application.
Hu G; Tu W; Yang L; Peng G; Yang L
Cancer Lett; 2020 Mar; 473():148-155. PubMed ID: 31911080
[TBL] [Abstract][Full Text] [Related]
13. A Signature-Based Classification of Gastric Cancer That Stratifies Tumor Immunity and Predicts Responses to PD-1 Inhibitors.
Li S; Gao J; Xu Q; Zhang X; Huang M; Dai X; Huang K; Liu L
Front Immunol; 2021; 12():693314. PubMed ID: 34177954
[TBL] [Abstract][Full Text] [Related]
14. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer.
Kim YB; Ahn JM; Bae WJ; Sung CO; Lee D
Int J Cancer; 2019 Aug; 145(4):916-926. PubMed ID: 30664822
[TBL] [Abstract][Full Text] [Related]
15. ARID1A Deficiency Is Associated With High Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma.
Iseda N; Itoh S; Yoshizumi T; Yugawa K; Morinaga A; Tomiyama T; Toshima T; Kohashi K; Oda Y; Mori M
Hepatol Commun; 2021 Apr; 5(4):675-688. PubMed ID: 33860125
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of PD-1 positive CD8 T-cells in gastric cancer.
Choo J; Kua LF; Soe MY; Asuncion BR; Tan BKJ; Teo CB; Tay RYK; So J; Shabbir A; Guowei K; Tan HL; Chan G; Ma H; Ramachandran GK; Lum JHY; Chee CE; Sridharan S; Tan P; Sundar R; Yong WP
Gastric Cancer; 2023 May; 26(3):393-404. PubMed ID: 36781556
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Significance of ARID1A Expression Patterns Varies with Molecular Subtype in Advanced Gastric Cancer.
Kim JY; Park CK; Noh S; Cheong JH; Noh SH; Kim H
Gut Liver; 2023 Sep; 17(5):753-765. PubMed ID: 36789575
[TBL] [Abstract][Full Text] [Related]
18. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.
Shen J; Ju Z; Zhao W; Wang L; Peng Y; Ge Z; Nagel ZD; Zou J; Wang C; Kapoor P; Ma X; Ma D; Liang J; Song S; Liu J; Samson LD; Ajani JA; Li GM; Liang H; Shen X; Mills GB; Peng G
Nat Med; 2018 May; 24(5):556-562. PubMed ID: 29736026
[TBL] [Abstract][Full Text] [Related]
19. Loss of ARID1A expression is associated with systemic inflammation markers and has important prognostic significance in gastric cancer.
Wang X; Che K; Shi T; Liu Q; Xu X; Wu H; Yu L; Liu B; Wei J
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1583-1595. PubMed ID: 35294647
[TBL] [Abstract][Full Text] [Related]
20. Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers.
Wang L; Qu J; Zhou N; Hou H; Jiang M; Zhang X
Biomed Pharmacother; 2020 Oct; 130():110626. PubMed ID: 32791396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
